Search

Your search keyword '"Templeton, Arnoud"' showing total 489 results

Search Constraints

Start Over You searched for: Author "Templeton, Arnoud" Remove constraint Author: "Templeton, Arnoud"
489 results on '"Templeton, Arnoud"'

Search Results

1. Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review

3. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

5. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review

6. Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

9. Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

12. Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer

14. The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study

16. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer

20. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

21. Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

22. Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer.

24. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

25. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition

26. Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival

27. Considerations for the clinical development of immuno-oncology agents in cancer

28. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer

33. Supplementary table 1 from Circulating DNA and Survival in Solid Tumors

34. Supplementary figures from Circulating DNA and Survival in Solid Tumors

42. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

45. Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)

46. Considerations for the clinical development of immunooncology agents in cancer.

49. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses

50. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

Catalog

Books, media, physical & digital resources